Related Experiment Video
Updated: Jun 26, 2026

Analysis of Iophenoxic Acid Analogues in Small Indian Mongoose (Herpestes Auropunctatus) Sera for Use as an Oral Rabies Vaccination Biological Marker
Published on: May 31, 2019
[Vigilance for veterinary medicinal products: declarations of suspected adverse reactions in the year 2007]
C R Müntener1, L Bruckner, A Stürer
1Institut für Veterinärpharmakologie und -toxikologie der Universität Zürich. cedric.muentener@vetpharm.uzh.ch
Abstract:
163 reports of suspected adverse reactions were received in the year 2007: 111 for veterinary medicinal (VMPs) and 52 for immunologic products. Half of the reported reactions for VMPs concerned either an antiparasitic drug (26%) or an antibiotic (24%). Reconversions (use in another target species or for another indication as registered) made the third most frequently mentioned group with 11 reports. For immunologicals, half of the declarations were related to an adverse reaction in dogs, the most frequently reported reaction in companion animals being allergies. Moreover, 272 enquiries were received by the Swiss Toxicological Information Center in Zürich. Most of these were related to dogs (73%) and the number of enquiries regarding VMPs correlated positively with the most frequently used therapeutic classes like antiparasitics (47%) and anti-inflammatory drugs (23%). The complexity of proscessing reports regarding the detection of residues in milk after prescribed withdrawal times is discussed in detail. In conclusion, the year 2007 is seen as a consolidation of the established system with a tendency towards increase in the number of complex cases.
Related Concept Videos
Pharmacovigilance
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
Drug Regulation
Pharmaceutical Poisoning: Potential Scenarios
Clinically Relevant Drug Product Specifications: Methods of Establishment
FDA Approved Drugs: Changes to Approved Drugs
Therapeutic Drug Monitoring: Affecting Factors

